Analyst Price Targets — PVLA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 7:33 pm | — | Truist Financial | $210.00 | $120.41 | TheFly | Palvella Therapeutics price target raised to $210 from $190 at Truist |
| February 24, 2026 6:49 pm | — | Chardan Capital | $210.00 | $118.61 | TheFly | Palvella Therapeutics price target raised to $210 from $174 at Chardan |
| February 24, 2026 4:25 pm | — | Stifel Nicolaus | $250.00 | $119.26 | TheFly | Palvella Therapeutics price target raised to $250 from $180 at Stifel |
| February 24, 2026 3:08 pm | — | H.C. Wainwright | $255.00 | $116.66 | TheFly | Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright |
| January 7, 2026 10:53 am | — | Mizuho Securities | $205.00 | $90.43 | TheFly | Palvella Therapeutics initiated with an Outperform at Mizuho |
| December 16, 2025 11:57 am | Whitney Ijem | Canaccord Genuity | $204.00 | $88.42 | TheFly | Palvella Therapeutics price target raised to $204 from $148 at Canaccord |
| December 16, 2025 11:54 am | Ryan Deschner | Raymond James | $193.00 | $91.51 | StreetInsider | Palvella Therapeutics (PVLA) PT Raised to $193 at Raymond James |
| December 15, 2025 9:21 pm | — | Chardan Capital | $174.00 | $88.42 | TheFly | Palvella Therapeutics price target raised to $174 from $110 at Chardan |
| December 15, 2025 8:02 pm | Jeff Mukherjee | BTIG | $192.00 | $88.42 | StreetInsider | Palvella Therapeutics (PVLA) PT Raised to $192 at BTIG |
| December 15, 2025 7:17 pm | — | Truist Financial | $190.00 | $88.89 | TheFly | Palvella Therapeutics price target raised to $190 from $105 at Truist |
Latest News for PVLA
Silo Pharma (NASDAQ: SILO - Get Free Report) and Palvella Therapeutics (NASDAQ: PVLA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk. Risk and Volatility Silo Pharma has a
BEYONDmLM.com campaign designed to educate, engage, and empower patients, caregivers , and healthcare professionals
Stock market volatility is rising as algorithms react instantly to global events, forcing investors to rethink traditional strategies.
WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it closed its…
Palvella Therapeutics, Inc. (NASDAQ: PVLA - Get Free Report)'s share price gapped up prior to trading on Thursday after Mizuho raised their price target on the stock from $205.00 to $250.00. The stock had previously closed at $128.60, but opened at $140.28. Mizuho currently has an outperform rating on the stock. Palvella Therapeutics shares last traded
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PVLA.
U.S. House Trading
No House trades found for PVLA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.